A, A 6-mm optical coherence tomography (OCT) B-scan with color overlay of flow signal (purple indicates retinal flow; red, choroidal flow). There is an abrupt transition zone between intact and atrophic retinal pigment epithelium and outer retina. An outer retinal tubulation (arrowhead), captured at an oblique angle, is present lateral to the region of intact retinal pigment epithelium. A prominent inner retinal vessel (circle) projects a dynamic shadow on deeper layers. Larger choroidal vessels (rectangle) abut the Bruch membrane in areas of choriocapillaris (CC) atrophy. B, En face OCT image of the segmented outer retina capturing the ellipsoid zone reflectivity, demonstrating a central island of relatively preserved ellipsoid zone with pseudopodial extensions. An oblique B-scan section through a pseudopod (arrowhead) corresponds to the outer retinal tubulation in panel A. Pseudopod length was measured as indicated with the blue line. B-F, Green line indicates the y-position of the B-scan in panel A. C, Choroidal angiogram demonstrating a central area of relatively intact CC with exposure of larger choroidal vessels in areas of CC atrophy (rectangle indicates choroidal vessels indicated by corresponding rectangle in panel A). D, Choriocapillaris angiogram obtained by segmentation of the decorrelation signal at the level of the CC, demonstrating that the greatest vessel density is associated with regions of intact outer retina. This image contains projection artifact from flow in large retinal vessels. D-F, Circle indicates the large retinal vessel from corresponding circle in panel A. E, Binary mask of retinal flow. Black pixels within this mask, consisting of 9.1% of the total number of pixels, are excluded in CC density calculations. F, Same image as in panel D with retinal vessels shown in purple for clarity. Large choroidal vessels (arrowheads) remain apparent in this CC angiogram owing to extensive CC atrophy. G, Mapping of CC density, showing regions of low CC density. Pixels containing retinal flow projection artifact are treated as empty pixels for density map generation.
A, En face optical coherence tomography (OCT) of ellipsoid zone (EZ) reflectivity demonstrates progressive EZ loss. B, Fundus autofluorescence imaging demonstrates relative preservation of retinal pigment epithelium autofluorescence corresponding to regions of intact EZ. Retinal pigment epithelium loss is more extensive than EZ loss in nearly all eyes. C, Choroidal angiogram demonstrates increasing degrees of CC atrophy with exposure of underlying choroidal vessels. D, Segmented CC angiogram demonstrates that CC density is subnormal in affected eyes throughout the imaged field but is worse underlying regions of EZ and retinal pigment epithelium loss. Projection artifact from large inner retinal vessels is indicated in purple. E, Mapping of CC density highlights areas of CC loss.
eTable. Electroretinography results and normative ranges.
eFigure. Spatial correlation of atrophy at different tissue layers in a man in his late 40s (top row) and a man in his mid-30s with more advanced disease (bottom row).
Jain N, Jia Y, Gao SS, Zhang X, Weleber RG, Huang D, Pennesi ME. Optical Coherence Tomography Angiography in ChoroideremiaCorrelating Choriocapillaris Loss With Overlying Degeneration. JAMA Ophthalmol. 2016;134(6):697-702. doi:10.1001/jamaophthalmol.2016.0874
Novel therapies for choroideremia, an X-linked recessive chorioretinal degeneration, demand a better understanding of the primary site(s) of cellular degeneration. Optical coherence tomography angiography allows for choriocapillaris (CC) imaging. We compared the extent of structural alterations of the CC, retinal pigment epithelium, and photoreceptors with multimodal imaging.
In a clinical case series conducted from September 15, 2014, through February 5, 2015, 14 eyes of 7 male patients with choroideremia (median age, 34 years [interquartile range, 15-46 years]; age range, 13-48 years), 4 eyes of 2 women with choroideremia carrier state (both in mid-50s), and 6 eyes of 6 controls (median age, 42.5 years [interquartile range, 33-55 years]; age range, 24-55 years) underwent multimodal imaging with optical coherence tomography angiography and electroretinography. The mean (SD) macular CC density was 82.9% (13.4%) in patients with choroideremia, 93.0% (3.8%) in female carriers, and 98.2% (1.3%) in controls. The mean (SD) CC density in affected eyes was higher in regions with preserved (92.6% [5.8%]) vs absent (75.9% [12.6%]) ellipsoid zone (mean difference, 16.7%; 95% CI, 12.1% to 21.3%; P < .001). Seventeen of 18 eyes of the patients and carriers had outer retinal tubulations forming pseudopod-like extensions from islands of preserved ellipsoid zone. Outer retinal tubulations were associated with absence of underlying retinal pigment epithelium and were longer (r = −0.62; 95% CI, −0.84 to −0.19; P < .001) and more numerous (r = −0.71; 95% CI, −0.91 to −0.27; P < .001) in more severely affected eyes.
Conclusions and Relevance
These findings suggest that regional changes in CC density correlate with photoreceptor structural alterations in choroideremia. Although closely coupled, the results suggest that retinal pigment epithelium loss is more extensive than photoreceptor loss.
Prior studies have variably implicated the retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris (CC) as the primary site(s) of degeneration in choroideremia, an X-linked recessive chorioretinal degeneration.1- 5 A recent gene therapy study targeted the RPE and photoreceptors.6 However, little is known of the role of the CC in disease progression, partly because of the difficulty with visualizing this tissue layer in vivo.
Optical coherence tomography (OCT) angiography (OCTA) permits CC imaging that is not possible with conventional angiography. We hypothesize that if coupled with en face imaging of the photoreceptors and RPE, OCTA will provide insights into the underlying pathobiology of choroideremia.
Question What are the primary sites of tissue degeneration in choroideremia?
Findings In this clinical case series of patients with choroideremia as well as choroideremia carriers, multimodal imaging including optical coherence tomography angiography demonstrated that retinal pigment epithelium loss exceeded photoreceptor loss in nearly all eyes. The mean choriocapillaris density was significantly lower in patients than in carriers and controls. In both patients and carriers, choriocapillaris density was significantly greater underlying regions with photoreceptor preservation as opposed to regions with photoreceptor loss.
Meaning In vivo study of this rare disease with multimodal imaging has implications for novel treatments such as gene therapy.
This study was conducted from September 15, 2014, through February 5, 2015, at the Oregon Health & Science University. The protocol and informed consent were approved by the Oregon Health & Science University Institutional Review Board. Written informed consent was obtained for all participants. The study adhered to the tenets of the Declaration of Helsinki7 and complied with the Health Insurance Portability and Accountability Act.
Patients with choroideremia, choroideremia carriers, and age-matched controls underwent OCTA imaging (Avanti RTVue XR; Optovue, Inc),8- 10 fundus autofluorescence imaging (200Tx; Optos, PLC), and full-field electroretinography (ERG) (custom ERG unit).11
En face outer retinal OCT images were constructed from the mean reflectance from a slab spanning 45 µm to 25 µm above the Bruch membrane. En face OCTA images were constructed at varying depths, with the CC angiogram representing flow data from a 10-µm-thick slab below the Bruch membrane. To account for projection artifact from overlying vessels, a mask of large vessels in the retinal angiogram was applied to eliminate those pixels from the CC angiogram (Figure 1).
Vessel density was computed as previously described.12 A CC density map was constructed (Figure 1) to better quantify local CC density as follows: a grid containing 8 × 8-pixel elements was created on the angiogram, and the proportion of flow pixels within each grid element defined the CC density within that element. Linear interpolation created the final CC density map.
Following manual image registration, regions of interest were manually delineated, including the region(s) of relatively preserved RPE on fundus autofluorescence images and relatively preserved ellipsoid zone (EZ) (including pseudopodial extensions) on outer retinal OCT images (Adobe Photoshop CS6; Adobe Systems Inc). The lengths of pseudopodial extensions of EZ were measured (Figure 1B), and the longest pseudopod for each eye was selected for analysis.
Comparisons between CC density were evaluated with the Wilcoxon signed rank test; comparisons between area of preserved RPE and EZ were performed with a paired t test. Correlations were computed with the Pearson correlation coefficient. The generalized estimating equation approach accounted for correlation between eyes of patients (SAS version 9.4 statistical software; SAS Institute, Inc).13
In this clinical case series, 14 eyes of 7 male patients with choroideremia (median age, 34 years [interquartile range, 15-46 years]; age range, 13-48 years), 4 eyes of 2 female carriers (both in mid-50s), and 6 eyes of 6 controls (median age, 42.5 years [interquartile range, 33-55 years]; age range, 24-55 years) were imaged. Best-corrected visual acuity ranged from 20/20 to 20/30 in affected males and 20/20 to 20/60 in female carriers (1 carrier had atrophic macular changes) (Table). The mean (SD) ERG scotopic 0.01 b-wave amplitude measured 23.0% (34.4%) (n = 12 eyes) and 121.0% (70.7%) (n = 2 eyes) of the lower limit of normal for affected and carrier eyes, respectively (eTable in the Supplement).
The mean (SD) CC density across all regions was 82.9% (13.4%) in the 14 eyes of patients with choroideremia, 93.0% (3.8%) in the 4 eyes of the carrier females, and 98.2% (1.3%) in the 6 control eyes (P < .05 for all between-group comparisons) (Table). The CC density was higher in regions with relatively preserved EZ as compared with regions with absence of EZ in both affected males (mean [SD], 92.6% [5.8%] vs 75.9% [12.6%], respectively; mean difference, 16.7%; 95% CI, 12.1% to 21.3%; P < .001; n = 14 eyes) and female carriers (mean [SD], 95.3% [0.75%] vs 81.3% [13.4%], respectively; mean difference, 14.1%; 95% CI, −7.1 to 35.2%; P = .08; n = 4 eyes) (Figure 2). There was a positive correlation between normalized ERG scotopic 0.01 b-wave amplitude and CC density (r = 0.50; 95% CI, 0.23 to 0.68; P < .001; n = 14 eyes).
Qualitative assessment of registered images demonstrated tight coupling of transition zones at the level of the EZ, RPE, and CC. Across all affected and carrier eyes, the mean (SD) areas of relatively preserved EZ (by OCT) and RPE (by autofluorescence) were 22.7 (9.2) mm2 and 20.8 (10.3) mm2, respectively (P < .001; n = 15 eyes). In 14 eyes of 7 participants, the area of relatively preserved EZ was larger than the corresponding area of preserved RPE. In 2 eyes of 1 patient with choroideremia, EZ loss exceeded RPE loss by autofluorescence imaging but not by infrared reflectance imaging.
Seventeen of 18 eyes of the patients and carriers had outer retinal tubulations (ORTs). In the en face perspective, these appeared as pseudopodial extensions emanating from a central island of relatively preserved outer retina (eFigure in the Supplement). There were a mean (SD) of 13.1 (7.8) and 4.3 (5.3) ORTs within the imaged field in affected eyes and carrier eyes, respectively. There was a negative correlation between normalized ERG scotopic 0.01 b-wave amplitude and both ORT number (r = −0.71; 95% CI, −0.91 to −0.27; P < .001) and ORT length (r = −0.62; 95% CI, −0.84 to −0.19; P < .001). There was no relative preservation of CC underlying the ORTs.
Multimodal en face imaging with OCTA demonstrated remarkably tight coupling of CC loss to overlying retinal and RPE degeneration. The most severely affected eyes had distinct transition zones between relatively preserved and diseased CC, whereas carrier eyes had patchy, poorly defined regions of CC loss.
En face outer retinal imaging in these eyes revealed a unique pattern of degeneration with a central island of relatively intact photoreceptors containing pseudopodial extensions of surviving tissue. The OCT sections demonstrate that these pseudopods represent scrolled outer retina and ORTs at the margins of degeneration. In the en face perspective, the ORT is characterized by an outer hyporeflective band that originates with photoreceptor cell nuclei, adjacent to a hyperreflective line that likely originates with the external limiting membrane and inwardly migrating inner segment mitochondria.14
Photoreceptor layer scrolling and ORT formation suggest that the underlying RPE and/or CC is not adequately supporting the retina and that photoreceptor death is a secondary process.14 The RPE loss exceeded the EZ loss in nearly all eyes, and ORTs consistently extended beyond the margins of preserved RPE. In more advanced cases, as measured by ERG response, ORTs were more numerous and longer. This finding suggests that with advancing degeneration, cells persist within relatively stabilized ORT structures, while the main island of retinal tissue becomes gradually smaller.
Of note, image grading was not subject to reproducibility studies, and it is unclear how these findings might vary if the same images were regraded by the same individual or others.
The split-spectrum amplitude-decorrelation angiography algorithm identifies vessels with flow greater than a minimum velocity. With a 70-kHz OCT system and 304 A-scans per B-scan, it should be sensitive to normal capillary flow speeds (0.4-3 mm/s).15,16 Absence of flow signal can occur at regions of low OCT reflectance such as beneath large retinal vessels. We accounted for this by masking retinal vessels and discounting those pixels during quantification.
En face multimodal imaging with OCTA reveals a range of CC alterations in choroideremia and suggests that RPE loss precedes photoreceptor loss. Optical coherence tomography angiography of the CC represents a new tool for the study of chorioretinal diseases and may provide additional insights into this important vascular plexus.
Corresponding Author: Mark E. Pennesi, MD, Casey Eye Institute, Oregon Health & Science University, 3375 SW Terwilliger Blvd, Portland, OR 97239 (email@example.com).
Submitted for Publication: January 24, 2016; final revision received February 25, 2016; accepted February 28, 2016.
Published Online: May 5, 2016. doi:10.1001/jamaophthalmol.2016.0874.
Author Contributions: Dr Jain had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Jain, Huang, Pennesi.
Acquisition, analysis, or interpretation of data: Jain, Jia, Gao, Zhang, Weleber, Huang.
Drafting of the manuscript: Jain, Pennesi.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Jain, Zhang.
Obtained funding: Jain, Jia, Weleber, Huang, Pennesi.
Administrative, technical, or material support: Gao.
Study supervision: Jia, Weleber, Pennesi.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Jia reported receiving research equipment, research grant, and patent royalty from Optovue Inc and being a licensee on pending patent “Split-Spectrum Amplitude-Decorrelation Angiography With Optical Coherence Tomography.” Dr Weleber reported receiving personal fees for consultation from Novartis and Pfizer; receiving financial support for research to Oregon Health & Science University from Sanofi; receiving research support, serving on a scientific advisory board, and receiving reimbursement for travel expenses from AGTC; receiving a grant and serving on scientific advisory boards for Foundation Fighting Blindness (this relationship has been reviewed and managed by Oregon Health & Science University); and having been issued US patent 8,657,446 for “Method and Apparatus for Visual Field Monitoring, Also Known as Visual Field Monitoring and Analysis, or VFMA.” Dr Huang reported having stock options in Optovue, Inc; receiving research equipment, research grant, and patent royalty from Optovue, Inc; receiving patent royalty from Carl Zeiss Meditec, Inc; and being a licensee on pending patent “Split-Spectrum Amplitude-Decorrelation Angiography.” Dr Pennesi reported serving as a consultant to AGTC, ISIS Pharmaceuticals, Sparks, and Sucampo Pharmaceuticals; receiving grant support as part of clinical trials for AGTC and Sanofi; and receiving grants from Foundation Fighting Blindness and Research to Prevent Blindness. No other disclosures were reported.
Funding/Support: This work was supported by grants DP3 DK104397 (Dr Jia), R01 EY024544 (Drs Jia and Gao), R01 EY023285 (Drs Huang and Gao), 1K08 EY0231186-01 (Dr Gao), DP3 DK104397 (Dr Gao), T32 EY23211 (Dr Gao), and 1K08 EY021186-01 (Dr Pennesi), core grant P30EY010572 to Casey Eye Institute, Oregon Health & Science University, and Clinical and Translational Science Award UL1TR000128 (Drs Gao and Huang) from the National Institutes of Health; Career Development Award CF-CL-0614-0647-OHSU (Drs Jain and Gao), Enhanced Career Development Award (Dr Pennesi), and a center grant (Dr Weleber) from the Foundation Fighting Blindness; a Career Development Award (Drs Jia, Gao, and Pennesi) and an unrestricted grant to Casey Eye Institute, Oregon Health & Science University from Research to Prevent Blindness; a grant from Optovue, Inc (Dr Huang); and a grant from the Choroideremia Research Foundation (Dr Pennesi).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Previous Presentation: This paper was presented in part at the 38th Annual Meeting of the Macula Society; February 26, 2015; Scottsdale, Arizona; and at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology; May 5, 2015; Denver, Colorado.
Additional Contributions: Catie Schlechter, MS, CGC, Casey Eye Institute, Oregon Health & Science University, Portland, provided guidance with molecular testing and interpretation; she received no compensation.